CANY
EGRX

Caxton Associates (New York)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Caxton Associates (New York)’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20,027
Closed -$389K – 629
2023
Q2 		$389K Buy
20,027
+1,414
+8% +$33.5K 0.06% 305
2023
Q1 		$528K Buy
+18,613
New +$553K 0.08% 249
2020
Q2 		– Sell
-4,571
Closed -$210K – 663
2020
Q1 		$210K Buy
+4,571
New +$229K 0.04% 339

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (New York)'s EGRX Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 20,027 shares — an estimated $389K sold.

Caxton Associates (New York) first reported a position in EGRX in Q1 2020 and held it in 3 quarters. The position peaked at $528K in Q1 2023. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • Caxton Associates (New York) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 20,027 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $389K.
  • Caxton Associates (New York) first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 3 quarters.
  • Caxton Associates (New York)'s Eagle Pharmaceuticals, Inc. position peaked at $528K in Q1 2023.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.